PHASE 1B STUDY OF THE SRC INHIBITOR DASATINIB WITH FOLFOX AND CETUXIMAB IN REFRACTORY METASTATIC COLORECTAL CANCER

被引：0
|
作者：
Kopetz, S. [1 ]
Wolff, R. [1 ]
Eng, C. [1 ]
Overman, M. [1 ]
Henry, L. [1 ]
Coulson, R. [1 ]
Garrett, C. [1 ]
Abbruzzese, J. [1 ]
Gallick, G. [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 15
页数：2
相关论文
共 50 条
  • [1] Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.
    Lieu, C. H.
    Wolff, R. A.
    Eng, C.
    Overman, M. J.
    Henry, L.
    Coulson, R.
    Garrett, C. R.
    Abbruzzese, J. L.
    Gallick, G. E.
    Kopetz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase IB study of Src inhibition with dasatinib in combination with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer
    Kopetz, Scott
    Wolff, Robert
    Eng, Cathy
    Henry, Laura
    Glover, Katrina
    Chang, David
    Overman, Michael
    Gallick, Gary
    Abbruzzese, James
    CANCER RESEARCH, 2008, 68 (09)
  • [3] A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
    Boland, Patrick M.
    Lenz, Heinz-Josef
    Ciombor, Kristen K.
    Florou, Vaia
    Pishvaian, Michael J.
    Cusnir, Michael
    Cohen, Deirdre
    Guo, Jessie Y.
    Tang, Min
    Rajagopalan, Prabhu
    Wiley, Sandra E.
    Ghalie, Richard G.
    Hochster, Howard S.
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 60 - 68
  • [4] Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
    Parseghian, Christine M.
    Parikh, Nila U.
    Wu, Ji Yuan
    Jiang, Zhi-Qin
    Henderson, Laura
    Tian, Feng
    Pastor, Brice
    Ychou, Marc
    Raghav, Kanwal
    Dasari, Arvind
    Fogelman, David R.
    Katsiampoura, Anastasia D.
    Menter, David G.
    Wolff, Robert A.
    Eng, Cathy
    Overman, Michael J.
    Thierry, Alain R.
    Gallick, Gary E.
    Kopetz, Scott
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4146 - 4154
  • [5] A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.
    Boland, Patrick M.
    Lenz, Heinz-Josef
    Cusnir, Mike
    Florou, Vaia
    Pishvaian, Michael J.
    Cohen, Deirdre J.
    Ciombor, Kristen Keon
    Winer, Arthur
    Guo, Jessie Yanxiang
    Algaze, Sandra
    Wiley, Sandra E.
    Ghalie, Richard
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS222 - TPS222
  • [6] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Cui, Can
    Wei, Wei
    Thumar, Jaykumar Ranchobdhai
    Uboha, Nataliya, V
    Hafez, Navid
    Lacy, Jill
    Fischbach, Neal A.
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan Reed
    Stein, Stacey
    Hochster, Howard S.
    CANCER, 2021, 127 (09) : 1417 - 1424
  • [7] A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
    Wainberg, Zev A.
    Messersmith, Wells A.
    Peddi, Parvin F.
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    Kozloff, Mark F.
    CLINICAL COLORECTAL CANCER, 2013, 12 (04) : 248 - 254
  • [8] Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
    Hong, David S.
    Morris, Van Karlyle
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Kee, Bryan K.
    Zinner, Ralph
    Fogelman, David R.
    Mistry, Reena
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study
    Oberstein, Paul Eliezer
    Moreno, Victor
    Raghav, Kanwal Pratap Singh
    Hong, Yong Sang
    Han, Sae-Won
    Su, Yu-Li
    Yuan, Ying
    Pietrantonio, Filippo
    Van Cutsem, Eric
    Eng, Cathy
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Bhattacharya, Rianka
    Maul, Raymond Scott
    Iwasawa, Ryota
    Schnepp, Robert W.
    Knoblauch, Roland Elmar
    Thayu, Meena
    Ho, Gwo Fuang
    Kim, Han Sang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 135 - 135
  • [10] Therapy with cetuximab and irinotecan in refractory metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (9): : 497 - 498
12345